Melissa V Rewolinski - 12 Jul 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Melissa V. Rewolinski
Issuer symbol
ABUS
Transactions as of
12 Jul 2023
Net transactions value
$0
Form type
4
Filing time
13 Jul 2023, 16:13:43 UTC
Previous filing
15 Sep 2022
Next filing
24 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +110,000 $0.000000 110,000 12 Jul 2023 Common Shares 110,000 $2.27 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on July 12, 2023, the date of the grant.
F2 The option will vest and become exercisable in three equal annual installments beginning one year from the grant date.